145 related articles for article (PubMed ID: 23095799)
1. Effects of carvedilol as third-line add-on therapy on blood pressure and glucose metabolism in type 2 diabetic patients with chronic renal disease stage 3 and above.
Yasuda G; Yatsu K; Yamamoto Y; Hirawa N
Kidney Blood Press Res; 2012; 36(1):131-8. PubMed ID: 23095799
[TBL] [Abstract][Full Text] [Related]
2. Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a drug use survey.
Mori Y; Nishikawa Y; Iizuka T; Zenimura N; Matsumoto T; Hiramatsu K; Komiya M
Drugs R D; 2011; 11(2):171-90. PubMed ID: 21679007
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of amlodipine/olmesartan ± hydrochlorothiazide in patients uncontrolled on prior calcium channel blocker or angiotensin II receptor blocker monotherapy.
Neutel J; Shojaee A; Maa JF
Adv Ther; 2012 Jun; 29(6):508-23. PubMed ID: 22773358
[TBL] [Abstract][Full Text] [Related]
4. [Assessment of antihypertensive monotherapies effectiveness by home blood pressure self-measurement in hypertensive patients].
Hanon O; Laroche P; Vidal JS; Pannier B; Postel-Vinay N; Vaisse B; Girerd X
Ann Cardiol Angeiol (Paris); 2012 Jun; 61(3):218-23. PubMed ID: 22695025
[TBL] [Abstract][Full Text] [Related]
5. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers.
Polónia J; Barbosa L; Silva JA; Bertoquini S
Blood Press Monit; 2010 Oct; 15(5):235-9. PubMed ID: 20577082
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
7. Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.
Okura T; Kojima M; Machida H; Sugiyama M; Kato T; Komada T; Miyazaki T; Ninomiya T; Ichikawa T; Nakatani K; Watanabe Y; Dohi Y; Ito M; Kimura G
J Hum Hypertens; 2012 Apr; 26(4):214-9. PubMed ID: 21412266
[TBL] [Abstract][Full Text] [Related]
8. Combination of angiotensin II receptor antagonist with calcium channel blocker or diuretic as antihypertensive therapy for patients with chronic kidney disease.
Ishimitsu T; Ohno E; Nakano N; Furukata S; Akashiba A; Minami J; Numabe A; Matsuoka H
Clin Exp Hypertens; 2011; 33(6):366-72. PubMed ID: 21797795
[TBL] [Abstract][Full Text] [Related]
9. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.
Huang RS; Cheng YM; Zeng XX; Kim S; Fu P
Chin Med J (Engl); 2016 Mar; 129(5):562-9. PubMed ID: 26904991
[TBL] [Abstract][Full Text] [Related]
10. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.
Katayama S; Yagi S; Yamamoto H; Yamaguchi M; Izumida T; Noguchi Y; Inaba M; Inukai K
Hypertens Res; 2007 Jun; 30(6):529-33. PubMed ID: 17664856
[TBL] [Abstract][Full Text] [Related]
11. Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial.
Wright JT; Bakris GL; Bell DS; Fonseca V; Katholi RE; McGill JB; Messerli FH; Phillips RA; Raskin P; Holdbrook FK; Lukas MA; Iyengar M
J Clin Hypertens (Greenwich); 2007 Nov; 9(11):842-9. PubMed ID: 17978591
[TBL] [Abstract][Full Text] [Related]
12. [Renoprotective effect of triple therapy with low-dose angiotensin receptor blocker, low-dose diuretic and Ca-antagonist in hypertensive type 2 diabetic patients with overt nephropathy].
Kuriyama S; Tomonari H; Ohtsuka Y; Ohkido I; Hosoya T
Nihon Jinzo Gakkai Shi; 2003; 45(4):367-71. PubMed ID: 12806973
[TBL] [Abstract][Full Text] [Related]
13. Current status of antihypertensive prescription and associated blood pressure control in Japan.
Mori H; Ukai H; Yamamoto H; Saitou S; Hirao K; Yamauchi M; Umemura S
Hypertens Res; 2006 Mar; 29(3):143-51. PubMed ID: 16755149
[TBL] [Abstract][Full Text] [Related]
14. Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients.
Bell DS; Bakris GL; McGill JB
Diabetes Obes Metab; 2009 Mar; 11(3):234-8. PubMed ID: 18564334
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
Petrella R; Michailidis P
Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
[TBL] [Abstract][Full Text] [Related]
16. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial.
Matsuzaki M; Ogihara T; Umemoto S; Rakugi H; Matsuoka H; Shimada K; Abe K; Suzuki N; Eto T; Higaki J; Ito S; Kamiya A; Kikuchi K; Suzuki H; Tei C; Ohashi Y; Saruta T;
J Hypertens; 2011 Aug; 29(8):1649-59. PubMed ID: 21610513
[TBL] [Abstract][Full Text] [Related]
17. Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial.
Zebrack JS; Munger M; Macgregor J; Lombardi WL; Stoddard GP; Gilbert EM
Pharmacotherapy; 2009 Aug; 29(8):883-90. PubMed ID: 19637941
[TBL] [Abstract][Full Text] [Related]
18. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
19. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study.
Jacob S; Rett K; Wicklmayr M; Agrawal B; Augustin HJ; Dietze GJ
J Hypertens; 1996 Apr; 14(4):489-94. PubMed ID: 8761899
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular and renal protection in type 2 diabetes mellitus: the role of calcium channel blockers.
Nosadini R; Tonolo G
J Am Soc Nephrol; 2002 Nov; 13 Suppl 3():S216-23. PubMed ID: 12466317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
